IBJNews

Lilly stops testing of experimental schizophrenia drug

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.

Development of pomaglumetad methionil was stopped after an analysis of a large-scale study found the drug appeared to be ineffective, the Indianapolis-based company said Wednesday in a prepared statement. The decision wasn’t based on safety, Lilly said.

Lilly also said Wednesday that pomaglumetad methionil didn’t show a benefit in a smaller study that looked at its benefits when combined with another treatment. Last month, the company announced the drug had failed in another large-scale study. Analysts had low sales expectations for the medicine, including ISI Group analyst Mark Schoenebaum, who, in July, estimated peak annual revenue of $250 million.

“I’m disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness,” Jan Lundberg, president of Lilly’s research laboratories, said in the statement. “While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly.”

Lilly is in need of new treatments as the drugmaker braces for the expected loss of as much as $7 billion in sales to generic competition over the next five years. The company now has 11 drugs in the final stages of testing.

The decision to stop the phase III study of pomaglumetad methionil is expected to result in a third-quarter pretax charge of $25 million to $30 million, or 2 cents a share after tax, the company said. The treatment was in the final stages of testing required to get U.S. regulatory approval.

Lilly shares slipped 4 cents, to $44.70 each, Wednesday in the opening minutes of trading.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT